CARMAT : 2015 financial agenda

150112_PR_FinancialAgenda_2015

PRESS RELEASE

2015 financial agenda

Paris, January 12, 2015

CARMAT (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart project, aiming to provide a therapeutic alternative for people suffering from end-stage heart failure, today publishes its indicative financial agenda for 2015.

This preliminary agenda may be modified.

Event	Dates
2014 full-year results	Wednesday, February 11, 2015
Shareholders' Meeting	Thursday, April 2, 2015
2015 half-year results	Thursday, September 10, 2015

●●●

AboutCARMAT:the world's most advanced total artificial heart project

Acredibleresponsetoend-stageheartfailure:CARMAT aims to eventually provide a response to a major public health issue associated with heart disease, the world's leading cause of death: chronic and acute heart failure. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from irreversible end-stage heart failure, the most seriously affected of the 20 million patients with this progressive disease in Europe and the United States.

Theresultofcombiningtwotypesofuniqueexpertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards®heart valves, which are the most used in the world, and the technological expertise of Airbus Group, world aerospace leader.

Imitatingthenaturalheart: given its size, the choice of structural materials and its innovative physiological functions, CARMAT's total artificial heart could, assuming the necessary clinical trials are successful, potentially benefit the lives of thousands of patients a year with no risk of rejection and with a good quality of life.

AprojectleaderacknowledgedataEuropeanlevel: with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by Bpifrance; a total of €33 million.

Stronglycommitted,prestigiousfoundersandshareholders:Airbus Group, Professor Alain Carpentier, the Centre ChirurgicalMarieLannelongue, TruffleCapital, a leading European venture capital firm, and the thousands of institutional and individual shareholders who have placed their trust in CARMAT.

For more information: www.carmatsa.com

●●●

1/2

Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in CARMAT ("the Company") in any country. This press release contains forward‐looking statements that relate to the Company's objectives. Such forward‐looking statements are based solely on the current expectations and assumptions of the Company's management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. The Company's objectives as mentioned in this press release may not be achieved for any of these reasons or due to other risks and uncertainties.
No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the Document de Référence filed with the Autorité des Marchés Financiers under number D.14-0145 on March 17, 2014 and the Note d'Opération that was approved with visa no. 11-308 on July 11, 2011, changes in economic conditions, the financial markets or the markets in which CARMAT operates. In particular, no guarantee can be given concerning the Company's ability to finalize the development, validation and industrialization of the prosthesis and the equipment required for its use, to manufacture the prostheses, satisfy the requirements of the ANSM, enroll patients, obtain satisfactory clinical results, perform the clinical trials and tests required for CE marking and to obtain the CE mark. CARMAT products are currently exclusively used within the framework of clinical trials. They are not available outside these trials or for sale.

●●●

CARMATMarcello Conviti CEO

Patrick Coulombier

COO

Valérie Leroy

Director of Marketing

& Investor Relations

Tel.: [phone] [e-mail]

Alize RP

Press Relations

Caroline Carmagnol

Tel.: [phone] [e-mail]

NewCapInvestor Relations & Strategic Communications

Dusan Oresansky

Emmanuel Huynh

Tel.: [phone] [e-mail]

Name: CARMAT

ISIN code: FR0010907956

Ticker: ALCAR

2/2